Secretin should not be used to treat autism, researchers say

July 19, 2005

The intestinal hormone secretin, considered by some to be a promising drug in the treatment of autism, does not improve the symptoms and should not be used to treat the disorder, according to a new review of studies.

After analyzing data from 14 high-quality studies involving 618 patients with autism disorders, Dr. Katrina Williams of the Children's Hospital at Westmeade, Australia, and colleagues found no evidence that doses of intravenous secretin improve the social, behavioral or communication problems associated with autism.

Secretin "should not currently be recommended or administered as a treatment for autism," the reviewers conclude. There were no serious side effects reported in any of the studies, but "more adverse events are likely to be reported if secretin is made widely available," Williams says.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

In 1998, a series of small studies by Karoly Horvath and others at the University of Maryland School of Medicine hinted that secretin might be useful in treating autism. In the studies, children with symptoms of autism and gastrointestinal disorders were given pig secretin as part of an endoscopic procedure to examine their digestive functioning. Horvath and colleagues reported, to their surprise, that some autism symptoms seemed to improve in children who received the hormone.

"Since then, the use of secretin has become widespread and it is currently being dispensed in many different forms and in countries where it is not licensed," Williams says.

Although several controlled studies have since found little evidence that the hormone can improve the key symptoms of the disorder, some people with autistic disorders and their families still hold high hopes for secretin. Stories of how the hormone has transformed some patients' lives and purchasing information for secretin can be found across dozens of Internet sites.

"The many needs of these individuals trigger hope for a cure," Williams says. "As a result, therapies like secretin have become widely used after limited reports of success."

In the 14 studies reviewed by Williams and her colleagues, patients were diagnosed with classic autism or similar disorder such as Asperger syndrome. The patients, ranging in age from 3 to 15 years old, were given either synthetic human secretin or pig secretin or a saline placebo intravenously.

The Cochrane reviewers found no evidence that secretin improved the core features of autism, such as problems with social interaction, impaired speaking skills and repetitive behaviors.

Despite the findings, parents of autistic children may not be willing to give up their faith in secretin. Williams and colleagues cite a 1999 study in which 63 percent of parents whose children received the hormone treatment remained interested in secretin, even after the treatment failed to produce significant improvements.

Parents and patients are intensely interested in autism treatments, but most suggested therapies for autism disorders are "invasive, time consuming and expensive, and there is little known about their potential to do harm," Williams says.

In the face of such daunting options, parents often turn to alternative or complementary medicine for their children, according to Dr. Susan Levy of the Children's Hospital of Philadelphia. At Children' Hospital, one in three children recently diagnosed with autism received alternative medical treatments, a 2004 survey by Levy and others found.

Autism disorders usually appear during the first three years of life, and may be four times more likely to occur in boys compared to girls. The prevalence of autism is disputed. A 2003 study estimated that 40 out of every 10,000 children in the United States might have an autistic disorder, but other studies estimate the prevalence as less than one out of every 10,000 children.

In recent months, some politicians and patients have also suggested that a mercury compound called thimerosal, formerly used as a preservative in vaccines, may be one of the culprits behind autism. Although the purported connection has been well publicized, the Institute of Medicine concluded earlier this year that there is no evidence of a link between vaccines and autism.

Autistic disorders are probably caused by a combination of genetic, environmental and brain development factors, Williams says.
-end-
FOR MORE INFORMATION
Health Behavior News Service: 202-387-2829 or www.hbns.org.
Interviews: Contact Katrina Williams at 61-298-452-006.
To receive a full copy of the review, contact Julia Lampam at 44-124-377-0668 or jlampam@wiley.co.uk

K.W. Williams et al. Intravenous secretin for autism spectrum disorder (Review) The Cochrane Database of Systematic Reviews 2005, Issue 3

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit http://www.cochrane.org for more information.

Center for Advancing Health

Related Autism Articles from Brightsurf:

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

National Autism Indicators Report: the connection between autism and financial hardship
A.J. Drexel Autism Institute released the 2020 National Autism Indicators Report highlighting the financial challenges facing households of children with autism spectrum disorder (ASD), including higher levels of poverty, material hardship and medical expenses.

Autism risk estimated at 3 to 5% for children whose parents have a sibling with autism
Roughly 3 to 5% of children with an aunt or uncle with autism spectrum disorder (ASD) can also be expected to have ASD, compared to about 1.5% of children in the general population, according to a study funded by the National Institutes of Health.

Adulthood with autism
The independence that comes with growing up can be scary for any teenager, but for young adults with autism spectrum disorder and their caregivers, the transition from adolescence to adulthood can seem particularly daunting.

Brain protein mutation from child with autism causes autism-like behavioral change in mice
A de novo gene mutation that encodes a brain protein in a child with autism has been placed into the brains of mice.

Autism and theory of mind
Theory of mind, or the ability to represent other people's minds as distinct from one's own, can be difficult for people with autism.

Potential biomarker for autism
A study of young children with autism spectrum disorder published in JNeurosci reveals altered brain waves compared to typically developing children during a motor control task.

Autism often associated with multiple new mutations
Most autism cases are in families with no previous history of the disorder.

State laws requiring autism coverage by private insurers led to increases in autism care
A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found that the enactment of state laws mandating coverage of autism spectrum disorder (ASD) was followed by sizable increases in insurer-covered ASD care and associated spending.

Autism's gender patterns
Having one child with autism is a well-known risk factor for having another one with the same disorder, but whether and how a sibling's gender influences this risk has remained largely unknown.

Read More: Autism News and Autism Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.